Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study

被引：0
|
作者：
JI Aróstegui
J Anton
I Calvo
A Robles
A Speziale
Y Joubert
G Junge
J Yagüe
机构：
[1] Hospital Clinic,
[2] Hospital Sant Joan de Déu,undefined
[3] Hospital La Fe,undefined
[4] Hospital La Paz,undefined
[5] Novartis Pharma AG,undefined
[6] Hospital Clinic,undefined
来源：
Pediatric Rheumatology | / 13卷 / Suppl 1期
关键词：
Withdrawal Period; Canakinumab; Periodic Fever Syndrome; Global Assessment Score; HIDS Patient;
D O I：
10.1186/1546-0096-13-S1-O58
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Long term safety and efficacy of open-label infliximab for SLE
    Aringer, M.
    Houssiau, F.
    Graninger, W. B.
    Feier, E.
    Steiner, G.
    Smolen, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 455 - 455
  • [42] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
    Sandborn, William J.
    Feagan, Brian G.
    Hanauer, Stephen
    Vermeire, Severine
    Ghosh, Subrata
    Liu, Wenzhong J.
    Petersen, AnnKatrin
    Charles, Lorna
    Huang, Vivian
    Usiskin, Keith
    Wolf, Douglas C.
    D'Haens, Geert
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129
  • [43] Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
    Chatham, W. Winn
    Furie, Richard
    Saxena, Amit
    Brohawn, Philip
    Schwetje, Erik
    Abreu, Gabriel
    Tummala, Raj
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 837 - 847
  • [44] Efficacy and Safety of Long-term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-label Study
    Forester, Brent
    Sajatovic, Martha
    Tsai, Joyce
    Kroger, Hans
    Pikalov, Andrei
    Cucchiaro, Josephine
    Loebel, Antony
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2015, 23 (03): : S170 - S171
  • [45] Efficacy and safety of long-term treatment with lurasidone in older adults with bipolar depression: results of a 6 month open-label study
    Forester, B.
    Sajatovic, M.
    Tsai, J.
    Kroger, H.
    Pikalov, A.
    Cucchiaro, J.
    Loebel, A.
    BIPOLAR DISORDERS, 2015, 17 : 132 - 132
  • [46] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
  • [47] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine, I
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rodriguez, Juan Cruz Rizo
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024,
  • [48] Maintenance of Long-Term Safety and Efficacy of Cannabidiol Treatment in Dravet Syndrome: Results of the Open-Label Extension Trial (GWPCARE5)
    Devinsky, O.
    Nabbout, R.
    Miller, I.
    Laux, L.
    Zolnowska, M.
    Wright, S.
    Roberts, C.
    EPILEPSIA, 2018, 59 : S73 - S73
  • [49] Long-term safety of nebulized formoterol in COPD: An open-label active-controlled extension study
    Donohue, James F.
    Hamania, Nicola A.
    Fogarty, Charles M.
    Campbell, Saminy C.
    Denis-Mize, Kimberly
    Rinehart, Mike
    CHEST, 2007, 132 (04) : 531S - 531S
  • [50] Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal
    Lemoine, Patrick
    Garfinkel, Doron
    Laudon, Moshe
    Nir, Tali
    Zisapel, Nava
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 301 - 311
12345